Papers in Blood Cancer Discovery
Page 2 · newest first
- Abstract A045: Integrated tumor genomics and peripheral immune profiling identify complementary biomarkers of response to frontline pembrolizumab in extranodal NK/T-cell lymphomaBlood Cancer Discovery · 2026
- A Patient-Derived Xenograft Repository Capturing Clinical and Molecular Heterogeneity of Large B-cell LymphomaBlood Cancer Discovery · 2026
- Abstract A044: hTid-1 (DNAJA3) in tumorigenesis: A potential regulator of lymphoma pathobiology and therapeutic targetBlood Cancer Discovery · 2026
- Abstract A046: Dynamic changes in peripheral blood immune cells are associated with response to targeted therapies in relapsed/refractory T-cell lymphomaBlood Cancer Discovery · 2026
- Abstract A017: A patient derived xenograft repository capturing clinical and molecular heterogeneity of large B-cell lymphomaBlood Cancer Discovery · 2026
- Abstract PR002: Bcl6 -driven Cd70 -deficient Diffuse large B-cell lymphomas originate from innate-like cells with blunted CD4+ cytotoxic T-cell immune surveillanceBlood Cancer Discovery · 2026
- Abstract A042: Genetic and microenvironmental determinants of site-to-site heterogeneity in follicular lymphomaBlood Cancer Discovery · 2026
- Abstract A006: Deleterious SPEN mutations induce epigenetic reprogramming to promote survival and enhance immune evasion pathways in an aggressive subset of BN2/C1 DLBCL tumorsBlood Cancer Discovery · 2026
- Abstract A002: Non-alpha IL2R agonist improves CAR T cell therapy by preventing CAR T dysfunction in relapsed/refractory large B cell lymphomaBlood Cancer Discovery · 2026
- Abstract A011: OSTM1 restrains B-cell lymphomagenesis by promoting PDE3B degradation and activating cAMP-PKA-CREB signalingBlood Cancer Discovery · 2026
- Abstract A056: Microenvironmental ecosystems in peripheral T-cell lymphomas reveal therapeutic vulnerabilitiesBlood Cancer Discovery · 2026
- Abstract IA007: Dark zone lymphomasBlood Cancer Discovery · 2026
- Abstract A012: USP11 links germinal center B-cell fate to adaptive immune crosstalk in immunized miceBlood Cancer Discovery · 2026
- Abstract A048: Surviving undiagnosed rare lymphoma: A patient perspective on diagnostic delays, treatment barriers, and advocacy in stage IV SPTCL with HLHBlood Cancer Discovery · 2026
- Abstract A057: Spatially resolved single cell atlas reveals niche-driven transcriptional rewiring across a B-cell lymphoma continuum and gives insights into transformationBlood Cancer Discovery · 2026
- Abstract A039: FFPE-CUT&Tag transcriptional activation mapping in FFPE patient biopsies reveals novel druggable pathways in lymphomaBlood Cancer Discovery · 2026
- Abstract IA009: Bispecific antibodies in B-cell lymphomas: Redefining immune engagement in the therapeutic landscapeBlood Cancer Discovery · 2026
- Abstract A037: FLIPI24 stratifies outcomes in follicular lymphoma treated with R2-based therapy: A pooled MD Anderson trial cohortBlood Cancer Discovery · 2026
- Abstract A021: Peripheral T cell lymphoma not otherwise specified: Characterization of pet dogs as a model organismBlood Cancer Discovery · 2026
- Abstract A019: Ex vivo modeling of immune interactions to improve immunotherapeutic efficacy in follicular lymphomaBlood Cancer Discovery · 2026
- Abstract A034: Unlocking BCMA in aggressive lymphomas: A native receptor-targeted peptide for theranostic applicationsBlood Cancer Discovery · 2026
- Abstract IA006: Resistance to BTK degradersBlood Cancer Discovery · 2026
- Abstract A029: c-MYC/BCL2 induced replication stress drives dependence on POLQ-mediated microhomology-mediated end joining in aggressive large B-cell lymphomaBlood Cancer Discovery · 2026
- Abstract A004: ROR1 upregulation after CD19-CAR T-cell relapse in mantle cell lymphoma reveals a targetable vulnerability for ROR1-directed bispecific modalitiesBlood Cancer Discovery · 2026
- Abstract A050: Immune checkpoint sensitivity through spatial reprogramming of the tumor microenvironment in T cell lymphomaBlood Cancer Discovery · 2026
- Abstract IA004: Targeting BTK in CLL and other B-cell Malignancies: Continuous Progress with a Continuous TherapyBlood Cancer Discovery · 2026
- Abstract A027: Combination targeted therapy with ViPOR in relapsed/refractory (R/R) and treatment-naïve (TN) mantle cell lymphoma (MCL): Analysis of safety, efficacy, and minimal residual disease (MRD)Blood Cancer Discovery · 2026
- Abstract A049: Spatially resolved microenvironment profiling reveals distinct follicular lymphoma archetypesBlood Cancer Discovery · 2026
- Tumor-infiltrating clonal hematopoiesis is associated with adverse clinical outcomes in diffuse large B-cell lymphomaBlood Cancer Discovery · 2026
- Abstract A040: Polyunsaturated fatty acids control lipid membrane dynamics and enable B-cell lymphomagenesisBlood Cancer Discovery · 2026
- Abstract A018: EMT-like reprogramming defines drug-tolerant persister cell plasticity in mantle cell lymphomaBlood Cancer Discovery · 2026
- Abstract A020: Characterizing the disease pathogenesis and translational potential of naturally occurring canine small cell B cell lymphomaBlood Cancer Discovery · 2026
- Abstract IA005: Analysis of site-specific CAR T cell efficacy in LBCL and development of novel engineering strategiesBlood Cancer Discovery · 2026
- Abstract IA001: T-cell lymphomas after CAR-TBlood Cancer Discovery · 2026
- Abstract A023: Different paths to the same destination: Molecular divergence and functional convergence in human and canine lymphomasBlood Cancer Discovery · 2026
- Abstract PR006: C5ORF30/MACIR is a regulator of HLA-DR expression and immune evasion in high-risk DLBCLBlood Cancer Discovery · 2026
- Abstract IA002: Hodgkin lymphoma tumor microenvironmentBlood Cancer Discovery · 2026
- Abstract A025: CFON-026, a novel macrocyclic BTK inhibitor disrupts scaffold-dependent signaling and overcomes resistance to BTK-directed therapiesBlood Cancer Discovery · 2026
- Abstract A032: Bispecific antibody dose optimization in a syngeneic lymphoma model and development of bispecific nanoshells (BINS) for enhanced immune targetingBlood Cancer Discovery · 2026
- Abstract PR005: Mutant FOXO1 licenses MYC transformation of human germinal center B cells into dark-zone MYC-BCL2 high-grade B cell lymphomasBlood Cancer Discovery · 2026
- Abstract IA010: TP53-independent risk stratification in mantle cell lymphoma using a novel gene expression signatureBlood Cancer Discovery · 2026
- Abstract A014: OR2B6 is a chemosensor associated with activated B-cell like diffuse large B cell and mantle cell lymphomaBlood Cancer Discovery · 2026
- Abstract A035: ER-associated retrotranslocation generates a cytosolic OSTM1 E3 ubiquitin ligase that targets PDE3B for degradationBlood Cancer Discovery · 2026
- Abstract A052: Lymformer: A Domain-Specific, Self-Supervised Vision Transformer for Survival Prediction Using Whole Slide Images in Diffuse Large B-Cell LymphomaBlood Cancer Discovery · 2026
- Abstract A038: Performance of classification models using limited genomic data in cases of newly diagnosed large B cell lymphomaBlood Cancer Discovery · 2026
- Abstract A051: Spatially dispersed MYC-BCL2 co-expressing cells confer poor survival in DLBCL through functional p53 loss and PGE2-mediated immune evasionBlood Cancer Discovery · 2026
- Beyond Static Subtypes in Large B-cell Lymphoma: Context, Plasticity, and Therapeutic LogicBlood Cancer Discovery · 2026
- Outcomes of CAR-T Cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple MyelomaBlood Cancer Discovery · 2026
- Genomic features do not account for differences in multiple myeloma risk by ancestryBlood Cancer Discovery · 2026
- KATs in the MYST: A New Therapeutic Vulnerability for SETBP1 -Mutated Myeloid MalignanciesBlood Cancer Discovery · 2026